Lingual angioedema associated with everolimus.
Mackenzie
Morgan
M
Dalhousie University, Halifax, Nova Scotia, Canada.
Wood
Lori A
LA
D000799:Angioedema / Q000139:chemically induced* / Q000188:drug therapy; D018926:Anti-Allergic Agents / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D004155:Diphenhydramine / Q000627:therapeutic use; D004837:Epinephrine / Q000627:therapeutic use; D000068338:Everolimus; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives*; D014060:Tongue Diseases / Q000139:chemically induced* / Q000188:drug therapy
D018926:Anti-Allergic Agents; D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D004155:Diphenhydramine; D000068338:Everolimus; D020123:Sirolimus; D008775:Methylprednisolone; D004837:Epinephrine